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Innovative 21st-century roadmaps need to be devised for biomedical research.
Advanced human biology-based models and tools hold the key to progress. 
Human disease pathways mapped at multiple biological scales are an important concept.
Funding should focus on acquiring critical human data instead of on animal models.
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Teaser: To discover and develop new therapies, we need 21st-century roadmaps for biomedical research based on 
multiscale human disease pathways, and supported by policy and funding strategies that prioritise human relevance.
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Decades of costly failures in translating drug candidates from preclinical disease models to human 
therapeutic use warrant reconsideration of the priority placed on animal models in biomedical 
research. Following an international workshop attended by experts from academia, government 
institutions, research funding bodies, and the corporate and nongovernmental organisation (NGO)
sectors, in this consensus report, we analyse, as case studies, five disease areas with major unmet 
needs for new treatments. In view of the scientifically driven transition towards a human pathway-
based paradigm in toxicology, a similar paradigm shift appears to be justified in biomedical 
research. There is a pressing need for an approach that strategically implements advanced, human 
biology-based models and tools to understand disease pathways at multiple biological scales. We 
present recommendations to help achieve this.
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To date, the discovery and development of new drugs have relied heavily on the use of preclinical animal 
models. However, it is widely recognised that this reliance on animal models, which recapitulate only limited 
aspects of human disease, is holding back progress in many areas [1,2]. The average cost of research and 
development for a successful drug is estimated to be US$2.6 billion [3] and the number of new drugs 
approved per billion US dollars spent has halved roughly every 9 years since 1950, decreasing around 80-
fold in inflation-adjusted terms [4]. More than 90% of compounds entering clinical trials fail to gain regulatory 
approval, mainly as a result of insufficient efficacy and/or unacceptable toxicity, because of the limited 
predictive value of preclinical studies [5].
The failure of animal studies to predict drug efficacy and toxicity in humans has several causes, including 
experimental design flaws and bias, but species variations are the most significant [6]. There is a growing 
recognition that, to increase the success rate, a stronger focus on human-relevant data is needed [7,8]. 
Animal research can provide useful in vivo data about selected pathologies already identified as significant, 
usually from human-specific studies. However, increasingly, this research could be conducted using 
innovative human- and disease-specific models and tools, thereby also eliminating the unsolvable problems 
of species variations.
To address the animal-model challenges of poor predictivity and cost-efficiency limitations, as well as 
incomplete knowledge of human biological pathways, toxicologists are beginning to move away from 
observing adverse effects in whole-animal models. Instead, they are looking towards measuring in vitro early 
endpoints that are predictive of adverse effects, using human cellular and molecular assays. This pathway-
based approach is embedded in an ‘adverse outcome pathway’ (AOP) framework, with a focus on the 
species of ultimate regulatory interest, that is humans rather than rodents, for human health risk assessment 
[8,9]. This framework allows the modelling of normal cellular signalling pathways that are perturbed by 
chemical exposure, and captures the consequential changes occurring at multiple biological levels in an 
individual, which eventually lead to adverse effects. An AOP is a conceptual construct representing existing 
knowledge to describe a sequence of causally linked events. This starts at the molecular level and 
progresses through different levels of biological organisation to an adverse health outcome in an individual 
(or population) [9].
Understanding AOPs in humans is enabling the emergence of a new predictive toxicology paradigm and has 
been adopted as part of the strategic research plan of the US Environmental Protection Agency (EPA) [10], 
and globally by the Organisation for Economic Cooperation and Development (OECD) [11]. The OECD AOP 
Development Program coordinates the efforts of its 34 member countries, offering a forum for international 
cooperation, common guidance (e.g., User Handbook; http://aopkb.org/common/AOP_Handbook.pdf) and 









knowledge management tools (e.g., the AOP Knowledge Base; http://aopkb.org).The OECD activity was 
initiated by toxicologists with the goal of providing improved tools for regulatory risk assessment, but the 
basic biology under investigation is the same as in biomedical research. Thus, both communities could 
benefit from the consolidation of expertise into common knowledge bases using a shared lexicon.
A workshop entitled ‘BioMed21: A Human Pathways Approach to Disease Research’, convened in 
December 2015 in Brussels, brought together leading health scientists, officials representing European 
institutions, national regulatory and research agencies, science-funding organisations, and other 
stakeholders, to discuss these issues. As case studies, research was examined into Alzheimer’s disease
(AD), autism spectrum disorders (ASD), cholestatic liver diseases (CLDs), respiratory diseases, and 
autoimmune diseases. Also considered were research funding frameworks and regulatory structures in the 
European Union (EU) and the USA. The workshop goal was to identify actionable consensus 
recommendations (Box 1) as a first step towards a comprehensive roadmap for human biology-based health 
research, as well as funding and policy frameworks.
Adverse outcome pathways
Some will argue that next-generation, human-specific techniques should complement rather than replace 
animal models in biomedical research and drug discovery [12]. However, a paradigm shift away from animal-
model reliance, as is happening in toxicology, is essential to overcome roadblocks in knowledge of human 
diseases and the discovery of effective therapies [13,14]. In 2016, the EU launched EU-ToxRisk, a 
€30 million flagship project to drive forward mechanism-based toxicity testing and risk assessment for the 
21st century (www.eu-toxrisk.eu/). The project consortium includes many of Europe’s leading toxicologists 
and experts in related fields; the project launch release stated: ‘These new concepts involve cutting-edge 
human-relevant in vitro non-animal methods and in silico computational technologies to translate molecular 
mechanistic understanding of toxicity into safety testing strategies. The ultimate goal is to deliver reliable, 
animal-free hazard and risk assessment of chemicals’.
Adapting the AOP concept, a critical part of the current transition underway in toxicology, would have great 
value for health research, drug discovery, and drug efficacy and safety testing. Mapping the perturbation of 
normal human biological pathways would, in many cases, be applicable both to efficacy and toxicity 
assessment, depending on whether the effect is desired. Thus, the disease pathways we envisage would 
link molecular initiating events through key events in cells, organs, and systems to disease outcomes in 
individuals (Figure 1). The AOP approach would help assign value to potential drug targets at an early stage 
(with obvious cost and time advantages), according to their roles in multiscale disease pathways, rather than 
merely considering an isolated disease mechanism or a solely molecular or cellular pathway [14].










AD is the most common form of dementia and is increasing in prevalence as human populations age. It is 
characterised by cognitive decline with distinctive brain pathologies, including regional loss of neurons with 
accumulation of amyloid beta (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau. These are 
accompanied by chronic inflammation and extensive oxidative damage. Dozens of strains of transgenic mice 
have been the dominant models in AD research for 15 years and have contributed to understanding some of 
the disease pathways underlying the condition. However, between 1998 and 2011, 100 compounds failed in 
clinical trials despite encouraging preclinical results [15] and none of 300 interventions tested in a transgenic 
mouse model, Tg2576, has gone on to clinical trials [16]. There have been no new therapies for AD for 10 
years and the five licensed drugs stabilise symptoms temporarily in only about half of patients and do not 
slow progression of the disease.
Reasons for the failure of potential new drugs for AD in clinical trials are multifactorial, but a major issue is 
the overdependency on inadequate animal models. Transgenic mouse models and transformed mammalian 
cell lines (widely used in drug screening and optimisation) substantially overexpress mutant proteins, and the 
simplistic cell models may not accurately represent native human neurons and their interactions with other 
brain cell types. These limitations contribute to drug development failures [17]. Transgenic mice only partially 
recapitulate the pathophysiology and aetiology of human AD, have a limited behavioural or cognitive 
repertoire, and have poor predictive validity for human AD [18].
It is essential to move away from inadequate animal models and simplistic cell systems and instead develop 
innovative human-specific approaches. These will allow a better understanding of normal human biology, 
more closely mimic disease pathology, and better recapitulate underlying disease pathways [19]. Significant
progress is being made with human induced pluripotent stem cells (hiPSCs) generated from donated 
somatic cells and differentiated into disease-specific and patient-specific neural cells. In one such model, 
neural cells derived from patients’ iPSCs expressed forebrain and neocortical markers as well as amyloid 
precursor protein (APP), β-secretase, and γ-secretase (involved in Aβ production), and secreted Aβ. Aβ 
production was reduced by secretase inhibitors and a nonsteroidal anti-inflammatory drug, suggesting that 
the model could be developed as a drug screen [20].
Patient-derived iPSCs differentiated into neural cells have been used to investigate AD-associated gene 
regulatory networks [21]. Phosphorylated tau was expressed and transcriptome analysis revealed significant 
gene expression changes associated with AD. This system could be used to study the underlying molecular 
basis of sporadic AD and for drug screening and toxicology. A 3D human stem cell model of AD has also 
recapitulated key pathological features, including Aβ plaques and neurofibrillary tangles [22]. hiPSC-derived 









neural cells are being developed as a microfluidic human brain model in vitro, which will likely have 
applications in research into AD, ASD, and other neurological disorders [23]. Microfluidic platforms with 
incorporated optogenetic neural cell stimulation enable high-resolution, light-controlled stimulation of 
individual neural cells to permit millisecond-by-millisecond studies of activity in vitro [24]. Collectively, this 
research reveals the potential of human neural models derived from hiPSCs to improve opportunities to 
study AD initiation and pathogenesis. This will clarify the roles of different cell types and identify potent and 
safe compounds preclinically. This would help to avoid failure in later-stage and costly in vivo animal or 
clinical studies.
Systems biology tools and computational modelling have important roles in integrating and interpreting 
multilayered, human-specific research data and in helping to unravel complex, nonlinear biological 
processes. The AETIONOMY project combined computational disease models with curated data and 
additional functionalities, such as literature mining, to support rational approaches for identifying disease 
mechanisms in neurodegenerative disorders [25]. A model for AD is based on biological expression 
language (BEL), which integrates molecular data, clinical information, neuroimaging data, and cognitive 
testing readouts. Initially, the project generated two mechanistic hypotheses [26] and, subsequently, has 
delivered more than 120 candidate mechanisms potentially involved in AD aetiology.
State-of-the-art clinical brain imaging can now generate high-resolution human structural and functional 
information, offering progress in finding novel, non-invasive imaging biomarkers for both the clinic and for 
drug discovery. Neuroimaging enables detailed studies of AD in humans in vivo, arguably the ‘gold standard’ 
model for any disease [20]. To maximise the value of human neuroimaging studies, the gap between clinical 
imaging and molecular biology needs to be bridged. A new computational method for AD can link 
neuroimaging biomarkers to their underlying molecular pathways. The approach integrates brain region-
specific molecular interactions, drug target information, and biomarker expression. This combined analysis 
approach can help identify relevant drug targets and reduce the risk of failure in clinical trials, because it 
uses human data instead of animal data that poorly reflect human neurodegenerative conditions [19].
Taken together, all these approaches demonstrate the feasibility of mapping human disease pathways at 
multiple scales. Integrating human in vitro, in vivo, and in silico data will enrich our understanding of human 
disorders and aid the discovery of new drug targets (Figure 2). Representing the current state of knowledge 
in computational models using a human pathways approach will enable the identification of knowledge gaps 
and the integration of new data into existing knowledge. As a result, we will build a more complete picture of 
complex disease pathophysiology.










ASD are lifelong developmental disabilities characterised by persistent deficits in social communication and 
interaction, and restricted, repetitive, and stereotyped patterns of behaviour. Different aetiologies can cause 
a similar behavioural outcome; consequently, many diseases with autistic features are grouped within ASD. 
The prevalence has increased dramatically over recent years. There are no specific therapies and most 
people with autism cannot live independently, underlining the need for better treatment options. The 
intrinsically human nature of ASD, its genetic heterogeneity, and the spectrum of clinical symptoms, together 
with a historical lack of living human brain cells for research, have, until recently, prevented progress in 
understanding disease pathways and in developing treatment approaches. The inherent differences between 
mouse and human genetic backgrounds and brain circuitry limit the value of rodent models of ASD [28[DE1]]. 
Drug discovery success for neurological disorders generally has been poor, mainly because of the lack of 
predictive validity of animal models [12].
Human in vitro models using reprogrammed patient somatic cells are an attractive option, because they 
capture a patient’s genome in relevant cell types and can recapitulate early stages of brain development. 
Given the unique nature of human cognition and behaviour, an in vitro human neurodevelopmental model 
could reveal biochemical and cellular features of conditions, such as ASD, that are difficult to reproduce in 
other models. Patient-specific iPSCs from individuals with confirmed diagnoses represent a powerful new 
approach, capturing both the primary genetic change and the genetic background [12]. Human stem cell 
biology, tissue engineering, bioinformatics, and machine learning have been combined to create an in vitro
human cellular model for developmental neurotoxicity screening [29]. The model comprises human 
embryonic stem cell-derived 3D neural constructs with vascular networks and microglia in a chemically 
defined synthetic hydrogel scaffold, which improves reproducibility. In a blinded trial, nine out of ten 
chemicals were correctly classified and the model could be useful in drug as well as chemical toxicity 
assessment.
Marchetto and colleagues used hiPSC-derived neurons and glial cells as a genetic model of ASD, to study 
Rett syndrome (RTT) [30]. RTT is a severe form of ASD caused by a genetic alteration in the gene encoding 
methyl-CpG-binding protein-2 (MeCP2). It presents with neurodevelopmental and speech delays that result 
in an autistic phenotype [30]. iPSC-derived neurons from patients with RTT showed reduced glutamatergic 
excitatory synapses, decreased frequency of spontaneous postsynaptic currents (as measured by whole-cell 
patch-clamping), and altered neuronal network connectivity. RTT neurons also had smaller neuronal somas 
and lower spine densities, similar to those seen in RTT postmortem brain tissues. Treating these RTT 
neurons with insulin growth factor 1 in vitro increased the number of glutamatergic synapses, indicating that 









such an approach could correct the RTT neuronal phenotype, as well as providing clues about dose and 
timing parameters. Thus. although still at a relatively early stage, hiPSC models have demonstrated the 
ability to recapitulate relevant neuronal defects occurring in ASD and show potential as drug-screening 
platforms [31].
hiPSC-derived RTT neuronal cultures and high-throughput robotics are being used with the aim of screening 
55 000 small-molecule drug candidates that might rescue the RTT synaptic defects, by the end of 2016 (A. 
Muotri et al., unpublished results, 2016). Validation of these findings can be carried out with hiPSC-derived 
3D neurospheres using multielectrode array assays, as in a recent study of a rare neurodevelopmental 
disorder called the MECP2 duplication syndrome [32]. A potential drug candidate not previously considered 
as a therapeutic candidate for neurological disorders appeared to rescue the aberrant morphology and 
ameliorate the functional phenotype [32]. These data indicate that hiPSCs can recapitulate some aspects of 
a neurodevelopmental disorder caused by genomic duplication, and can also be used in in vitro assays to 
screen potential drugs. hiPSC models allow manipulation of phenotype changes with candidate drugs, 
offering rapid, disease pathway-based, and species-specific drug screening platforms. Using mouse models, 
the research would have taken much longer and the results would not necessarily predict the human 
response.
For research into ASD and other diseases, innovative strategies are needed to collect biological material and 
clinical information, including biomarkers, from large patient cohorts. This will improve the validity of new 
models and increase the statistical power to distinguish information from noise caused by the variability 
introduced by reprogramming and differentiation methods. The EU-AIMS project of the Innovative Medicines 
Initiative (IMI) in Europe is a private/public initiative involving patient organisations in Europe and the USA, 
aiming to improve drug discovery for autism. Although much of this research is still focussed on mouse 
models, an important initiative is a European biobank. This has been set up to aid the generation of ASD-
specific hiPSCs to produce differentiated, characterised neurons for autism research. Research into 
neurological disorders is already benefiting from hiPSC-disease modelling because of its capability for 
generating disease-relevant cell types in vitro from the central nervous system, previously only available 
from postmortem samples [33]. Data from other approaches, such as human brain imaging, population 
genetics, systems biology, and computational modelling, should be integrated to generate novel hypotheses 
that can be tested using stem cell-derived human brain cells.
Cholestatic liver diseases
CLDs involve perturbed bile acid homeostasis and impaired liver function resulting from the blockage of bile 
flow. Although genetic factors and adverse drug effects are the main causes of CLDs, the so-called 









‘diseases of civilisation’, such as obesity and diabetes, are also implicated [34]. CLDs are often chronic and 
lead to overall liver damage. Progression to cirrhosis means that many patients with CLDs require liver 
transplantation. Given that few therapeutic options currently exist (mostly symptomatic relief), there is a 
pressing need to develop new treatment approaches.
Despite studies in many animal models and substantial clinical data, there have been limited advances in 
developing treatments for CLDs. Animal models have provided mechanistic insights into CLDs, but direct 
extrapolation of animal data to human physiology has been challenging. This is because of significant 
species differences in gut and liver physiology and in pathogenesis. In vivo animal models differ from 
humans in bile acid composition, transporter activities, immune and inflammatory responses, cytochrome 
P450 enzymes, gut microbiota, and mechanisms of parenchymal injury [34]. By contrast, current in vitro
models are generally 2D monocultures, unrepresentative of the 3D architecture of liver tissue, and are often 
derived from rodent primary cells or transfected cells. In vitro CLD models should ideally reflect the 
complexity of human in vivo liver function.
Over the past few years, there have been rapid developments in cell culture and analytical techniques that 
enable CLDs to be studied in vitro. These include using human-derived cells, such as primary hepatocytes, 
genetically modified human cell lines, and hiPSC-derived liver models. For example, differentiated human 
HepaRG cells (a human hepatoma cell line) are increasingly being used in drug uptake, metabolism, and 
elimination studies [35]. HepaRG cells have metabolic activity and functional main hepatobiliary transporters 
[36]: in a study involving drug-induced cholestasis, they were considered suitable for investigating 
pathophysiological mechanisms of CLDs [37].
A 3D environment allows the improved expression of metabolising enzymes and transporters in vitro [38]. In 
3D cultures, HepaRG cells develop a network of bile canaliculi and functional bile acid transporters, offering 
an important tool for studying CLDs. In the EU-NOTOX project of the Safety Evaluation Ultimately Replacing 
Animal Testing (SEURAT) initiative, HepaRG cells were used to investigate cholestasis in acute and chronic 
situations, focussing particularly on the effect of bile acid load and the mechanisms of drug-induced 
cholestasis. Chlorpromazine, known to induce CLD, disrupted the bile canaliculi network in 3D HepaRG 
spheroids, which confirmed their value in studying drug effects [39]. Exposure of HepaRG cells to bile acids 
in vitro caused cell death by necrosis, as mainly occurs in human CLDs. This contrasts with the apoptosis 
seen in rodent hepatic cells, further supporting these human-specific models [40]. 3D multicellular systems 
could help bridge the gap between conventional 2D models and in vivo clinical studies in humans.
Other human-specific in vitro models include primary human hepatocytes, precision-cut liver slices, and liver 
cells derived from hiPSCs, supported by technologies including perfusion bioreactors and microfluidic 









platforms. These enable high-throughput screening, high-content imaging, and computer modelling, as well 
as the application of the ‘omics in vitro. A human liver microfluidic device with variable perfusion rates has 
been developed that is compatible both with human primary hepatocytes and with patient-specific, iPSC-
derived hepatocyte-like cells [41]. 3D organoids, with hepatocytes alone or in co-cultures, maintained stable 
hepatic function, such as albumin secretion and metabolic activity, for up to 28 days.
In liver research, as in other fields, there are conceptual and data gaps between in vitro findings and clinical 
knowledge and information that need to be bridged so that the different research communities can 
communicate and benefit from each others’ work. The bridge could be via the defining of ‘disease AOPs’ that 
connect molecular- and cell-level data, through key events, to the clinical picture (Figure 3). Human data are 
the benchmark, and efforts are needed to expand clinical studies as well as histological analyses of ex vivo
tissue samples (e.g., blood, serum, and urine) and postmortem tissues from patients with disease. Both liver 
disease research and liver toxicology can benefit from a synergistic approach based on the AOP framework. 
This provides a powerful tool that will assist in integrating data from various sources, aiding mechanistic 
understanding, identifying human biomarkers, locating uncertainties, and helping direct future research.
An AOP for drug-induced cholestasis was published in 2013. It spans events at molecular, cellular, organ,
and individual levels, with bile salt export pump inhibition as the molecular initiating event (MIE) and 
cholestasis as the adverse outcome [42]. Key events include the accumulation of bile, the induction of 
oxidative stress and inflammation, and the activation of three nuclear receptors. Together with other 
intermediate steps, this MIE and subsequent key events drive both an adverse cellular response, which 
underlies directly caused cholestatic injury, and an adaptive cellular response to the primary cholestatic 
insults. Direct as well as secondary inducing and inhibiting effects of oxidative stress and/or inflammation are 
included. The AOP is highly relevant both to toxicology and liver disease research and illustrates the 
potential for the AOP concept to assist in understanding pathophysiology and identifying druggable targets.
Integrating data from the ‘omics technologies and innovative human cell models, combined with 
computational modelling, will enhance understanding of CLD pathways and improve predictive modelling. A 
pathways-based systems approach is important for bringing together these emerging data and to develop 
novel therapy options. Additionally, better collaboration between healthcare professionals and scientists in 
different disciplines from academia and industry will also be fruitful.
Respiratory diseases: asthma and cystic fibrosis
Asthma is a common, complex, and heterogeneous condition, affecting an estimated 20% of children and 
10–15% of adults. It is essentially a chronic inflammatory disease of the airways and, although most patients 
with asthma respond well to conventional anti-inflammatory agents, these are not a cure and the disease 









returns when drugs are withdrawn. Five percent of patients with asthma do not respond to inhaled or even 
oral corticosteroids.
Few new drugs have reached the clinic over the past 50 years despite considerable research funding and 
effort. The reliance on animal models has signally failed to provide novel therapies that translate into humans 
[43,44]. A comprehensive understanding of asthma pathophysiology is still lacking and there is an excessive 
focus on asthma as an allergic inflammatory condition. both attributable, in large part, to a reliance on animal 
models. Many drugs that appear promising in preclinical animal studies fail in humans because of the lack of 
safety and/or efficacy, given that asthma is unique to humans. The common mouse models do not 
recapitulate the complexity of asthma and, thus, a new approach to drug discovery and development is 
necessary [45]. There are striking differences between animal species and strains compared with human 
asthma, in terms of genetic basis, anatomy, physiology, underlying mechanisms, pathological response, and 
responsiveness to drugs [46]. Mouse models offer an integrated pathophysiological system for studying 
airways inflammation and hyper-responsiveness, but these characteristics are notably different from those 
observed in patients with asthma [47].
While improvements in animal models are being made, these ‘cannot bridge the chasm between the models 
and the myriad complexities of the human disorder and multiple asthma endophenotypes’ [46]. A greater 
focus is needed on human-specific airways models ex vivo and in vitro, as well as the use of other clinical 
samples, to improve translational success. There is now growing recognition that not all patients with asthma 
are allergic and that asthma is a syndrome. This underlines the need for better research to understand the 
underlying mechanisms as well as the pathophysiology in different subsets of patients.
The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) program, 
funded by the IMI, is taking a systems approach to researching severe asthma with the aim of mapping 
multiple ‘omics data (e.g., metabolomics, proteomics, and genomics) onto tissue samples from patients and 
their clinical and physiological data. New bioinformatics and mathematical approaches are being applied to 
generate novel clinical asthma classifications and to enable novel disease-associated pathways to be 
investigated. As part of the U-BIOPRED project, patients with severe asthma from across Europe have been 
recruited and a range of their tissue samples, including plasma, urine, sputum, and biopsies, has been 
biobanked for the acquisition of ‘omics data. Biomarker signatures, derived from a combination of clinical and 
high-dimensional biomarker data, are collected within a single technical platform. These data are being
mapped to data from preclinical human cellular and tissue models, as well as mouse and guinea pig models.
Combined clinical and biomarker data are also collected using multiple technical platforms. In a pioneering 
approach, machine learning is applied to create topological networks. This reveals statistically significant 









patterns, including clustering of sputum lipidomics and proteomics data among patients, yielding several 
clear subgroups of asthmatics. A key finding was that eosinophil-predominant asthma was driven by at least 
two distinct clusters of genes. These clusters differed from those characteristic of neutrophilic and other 
types of asthma [48]. This could lead to the molecular phenotyping of patients and the identification of 
disease-relevant mechanisms, rather than the current clinical signs and symptoms approach, which has not 
resulted in effective treatment. A similar approach using topological data analysis has demonstrated clear 
subsets of patients with severe eosinophilic and neutrophilic asthma [49]. These data can be compared with 
other databases and signatures to assess different disease models and treatment effects. For example, 
although the chronic house dust mite mouse model uses a clinically relevant allergen and is reproducible, it 
is not predictive of steroid responsiveness in patients with severe asthma. Examining the enrichment of 
specific signatures associated with distinct asthma subphenotypes could indicate which, if any, this model 
mimics. These disease signatures can also be examined in some of the new 3D organoid culture systems 
being developed [50] and in combination with other structural and immune cells, particularly from patients.
Functional genomics helps clarify links between genotype and phenotype on a genome-wide scale. It also 
aids the study of molecular mechanisms and pathways of disease, including gene–environment interactions,
and it offers a tool to generate novel hypotheses. Functional genomics studies in asthma have used 
endobronchial biopsies, epithelial brushings, bronchoalveolar lavage, and ex vivo cultured cells from patients 
with asthma and healthy controls. The results have led to the identification of potential new asthma 
subphenotypes, biomarkers, and treatment strategies [51,52]. The value of functional genomics would be 
improved if better bioinformatics programs were available to manage and interpret large-scale data sets. 
Promising future approaches include the study of more homogeneous, sorted cell populations or single 
human cells obtained by techniques such as laser capture microdissection. Together with functional 
genomics methods, these will capture benchmark patterns from multiple analyses of these cells.
Many asthma researchers see clear benefits to increasing the use of human tissue in research, including a 
greater knowledge of pathophysiology and quicker development of effective new therapies [44]. Access to 
normal and diseased human tissue is seen as a major barrier with significant logistical hurdles to overcome. 
Worldwide, human lung tissue is wasted; better cooperation is needed between pathologists, transplant 
surgeons, and researchers to increase its availability for research. This is an important issue for all disease 
areas. Progress has been made, for example, in heart research, where multiscale functional physiological 
data have been obtained from explanted human hearts in vitro using an array of imaging modalities. This has 
already indicated significant differences between animal models and human heart disease and provides a 
quantitative foundation for multiscale physiological models of the human heart [53]. Half of asthma 









researchers surveyed agreed that journals need to be willing to publish human tissue research without 
accompanying animal model data [44]. This would increase the evidence base supporting the use of human 
tissue models and provide confidence to encourage their wider uptake.
A group at the University of Aston, Birmingham, UK, has developed a multicellular in vitro model of human 
airways for research into cystic fibrosis (CF). The healthy model incorporates human pulmonary fibroblasts in 
human type IV placental collagen on a porous membrane above culture medium, the fibroblasts overlaid with 
ciliated airways epithelial cells with an air–liquid interface [54]. The epithelium is stratified and differentiated 
and tight junctions apically provide a resistant barrier, permitting analysis of whether responses occur 
apically or basally. There are functional cilia and mucus secretion, and the model replicates the mucociliary 
‘escalator’ that functions in vivo.
When populated with a CF airways epithelial cell line, the model showed similarities to the human disease, 
including a hyperinflammatory response with increased production of proinflammatory mediators compared 
with the healthy lung model (L.J. Marshall et al., unpublished data, 2016). The CF model also recapitulated 
susceptibility to three of the commonest respiratory pathogens associated with the disease. Gene expression 
studies showed that potential treatments are effective in the CF model versus the healthy lung model. Most 
promisingly, ivacaftor, which facilitates increased chloride transport by potentiating open-channel probability 
in the CF transmembrane conductance regulator, increased this activity in epithelial cells in the CF model. 
Microfluidic systems utilising human cells also show promise: a modular microfluidic model of human airways 
replicated the changes in oxygen tension in different compartments of CF airways [55]. The device was used 
to study antibiotic treatment of Pseudomonas aeruginosa, the bacteria mainly responsible for morbidity and 
mortality in CF. A mechanically active human lung-on-a-chip microfluidic platform has also been developed 
that reproduces complex organ-level responses to bacteria (Escherichia coli) and to inflammatory cytokines 
introduced into the alveolar space [56].
3D human tissue constructs can benefit from the use of natural or synthetic scaffolds. Scaffolds create a 
more life-like microenvironment, supporting cell growth, and encouraging efficient differentiation of hiPSCs. 
They can also improve cell co-culturing, tissue architecture, and cell functionality [57]. To assess the 
strengths and weaknesses of 3D models, we need comparisons of those currently available. They include 
precision-cut human lung slices, used to study replicating human rhinovirus 1b in airway epithelial cells; 
human bronchospheres, which have different cell layers, beating cilia, and mucus production; human 
bronchotubules, in vitro organoids with lumens that constrict in response to bronchostimulants; and co-
culture models of human airways.









These human-biology based models are promising, but to validate their reliability, the data need to be better 
mapped to human disease subsets, and the ‘omics could provide better discrimination for this purpose. 
Looking to the near future, 3D printed organs might also have an impact. These in vitro developments, 
combined with systems approaches and ‘omics analyses, as well as advances in clinical airways imaging, 
could well revolutionise research into respiratory diseases.
Autoimmune disease
Autoimmune diseases, such as autoimmune vasculitis, are exquisitely human illnesses with complex genetic 
backgrounds and variable clinical presentation. They range from local to systemic conditions and from acute 
to lifelong chronic diseases. The underlying pathophysiology is currently insufficiently understood and 
treatment is mainly empirical, with limited efficacy and significant adverse effects. Until now, autoimmune 
diseases have been studied mainly using a variety of cell-based in vitro assays using relatively simple 
cultures and in animal models. The cell culture systems lack many elements of clinical disease, and the 
animal models are intrinsically flawed because the animal immune system, particularly that of rodents, differs 
in several crucial aspects from the human immune system. Even mouse models based on a ‘humanised’ 
immune system lack the complex genetics underlying human autoimmune disease and organ/tissue 
antigens are nonhuman. This limits recapitulation of the immune response and tolerance mechanisms seen 
in human disease [58]. Improved understanding of human pathophysiology is essential to develop more 
effective targeted therapy for personalised treatment, implying a need for human investigational disease 
models for immune-mediated diseases.
Autoimmune (i.e., antineutrophil cytoplasmic antibody-associated) vasculitis is an example of an immune-
mediated disease. Patients with this condition have vascular inflammation with inflammatory leukocytes in 
blood vessel walls. This results in obstruction of blood vessel lumens leading to downstream ischaemia, 
tissue necrosis, and bleeding through the damaged blood vessel wall. Microfluidic organ-on-chip systems 
with hiPSC-derived differentiated cell and tissue cultures open the door to new approaches. They are human
specific and allow the independent variation of selected molecular factors and individual cell types, while 
simultaneously measuring system-level responses in real time [59]. They facilitate long-term co-culture of 
human cells with properties more closely recapitulating the human in vivo situation than did previous, 
simplistic 2D cell cultures. The essential elements of organ-on-chip models for immune-mediated vasculitis 
are a dual-chamber chip containing three cell types [human organ-specific (e.g., lung) endothelial cells in 
culture, immune cells and target organ tissue], a readout system, and a computational disease model that 
can fit new information gained into broader information on the disease.









In vitro microfluidic chip-based models use advances in human stem cell technology, microfluidics, 
microelectronics, and microfabrication. The new stem cell technologies enable the derivation of iPSC lines 
from patients and differentiation to the cell types required. The model can be relatively simple or more 
complex depending on the research question. Mechanisms of end-organ damage caused by circulating 
autoantibodies can be investigated with a relatively simple model based on a blood vessel on-a-chip (e.g., 
[60]) perfused with antineutrophil cytoplasmic antibodies and neutrophils derived from blood. A more 
complex model incorporating tissues from the immune system is needed to unravel the pathogenesis of 
autoimmune vasculitis.
Investigation of the innate immune response in immune-mediated vasculitis could be relatively simple 
because no human leukocyte antigen (HLA) matching between immune cells and target tissue in culture is 
required. Primary human blood cells (monocytes and neutrophils) can be used or, alternatively, specific cell 
lines or hiPSC-derived blood cells. Studies of the adaptive immune response need models that include 
peripheral lymphoid organs, such as the lymph node. Those looking at the development of an immune 
response or tolerance require culture of primary lymphoid organs, such as the thymus and bone marrow. 
Alternatively, HLA-identical iPSCs from patients’ cells have been used for the culture of the endothelial cell 
layer, for example. Studying inflammatory responses involves use of tissue- or organ-located dendritic cells 
and circulating cells, including monocytes and neutrophils. All of these cells and tissues have already been 
derived from hiPSC in vitro (e.g., [61,62]). A human artificial lymph node culture model (HuALN) with 
relevance to these approaches has been developed as a 3D microfluidic culture system for studying the 
induction or modulation of cellular and humoral immune responses [63]. HuALN utilises primary human 
leucocytes from healthy adult donors as the basis of the antigen-dependent, immune-competent lymph node 
micro-organoids, maintained in a long-term 3D matrix-assisted co-culture system. HuALN has a broad panel 
of read-out parameters, including metabolics, cellular analytics, antibody secretion, genomics and 
proteomics, cytokine and chemokine secretion, histology, and imaging.
A human organ-on-chip model for autoimmune vasculitis could be used at various stages in the development 
process for new drugs and treatments. It would also find applications in the discovery and/or validation of 
companion diagnostic assays to predict human efficacy and toxicity of lead drug candidates, for the purpose 
of patient stratification. It would reduce associated costs and should decrease late-stage failures in clinical 
trials. Investigational work with organ-on-chip and 3D culture systems, combined with knowledge-based 
computational disease modelling, carries the promise of defining cellular and organ-level disease pathways 
and filling in missing information on human disease pathophysiology in autoimmune diseases.









So far, the benefits of microfluidic systems have been mainly recognised within a small scientific community. 
Off-the-shelf availability of microfluidic devices and their components, perhaps on a modular basis with plug-
in connections, will make these systems more user friendly. Active dialogue will be needed, particularly with 
pharmaceutical companies and regulatory authorities, to create wider awareness of the potential of organs-
on-chips in research and testing.
Discussion and recommendations
Workshop participants agreed that reviews of therapeutic progress in several disease areas confirmed that 
continued reliance on animal models is unlikely to improve the currently poor rate of clinical approval of new 
treatments. There is a pressing need for innovative research roadmaps that focus on understanding human 
disease pathophysiology and defining disease AOPs at multiple biological levels, from molecular 
mechanisms to adverse outcomes in patients. They should incorporate 21st-century advances in human-
specific tools and models, and funding should be prioritised for the development and validation of next-
generation human-based approaches.
An adapted AOP concept, a critical part of the current transition underway in toxicology, would have great 
value in biomedical research: for defining human pathophysiological pathways for drug discovery and for 
drug efficacy and safety testing. Disease AOPs would provide clear mechanistic rationales for diagnostic, 
preventative, and therapeutic interventions, including personalised medicine. This requires strong 
multidisciplinary collaboration, based on mutual understanding among disciplines such as physics, 
chemistry, engineering, cell and molecular biology, stem cell biology, clinical medicine, and advanced 
bioinformatics.
Disease research roadmaps
Disease research roadmaps that focus on human biology-based models and approaches need to be 
developed, involving a gap analysis to identify what human pathophysiological knowledge is currently lacking 
in each disease area, and whether we have the technologies and models to acquire it. The AOP concept 
provides a framework for assembling existing knowledge and identifying those gaps.
In terms of advanced in vitro human cell models, several breakthroughs have been made in recent years. 
hiPSCs allow human-, disease- and patient-specific approaches to studies in vitro: the technology is still 
developing but progress is rapid. Generating high-quality hiPSC lines is time consuming and expensive, 
although the costs are decreasing, and programming and quality control approaches need to be 
standardised to improve interlaboratory reproducibility. Microfluidics platforms, as well as 3D culture 
systems, create reproducible models that recapitulate human disease pathophysiology more completely than 
before, and are accessible to real-time multiplexed analysis of structure and function. Genome editing in vitro









is another recent advance that will be fruitful in identifying gene variations that are causative rather than 
merely being on the disease pathway of interest. These human-specific in vitro models are promising, but 
require funding for further development and to map the data they produce onto human (clinical) disease 
information. The reliability of these models could be assessed by using ‘omics data. hiPSC-derived culture 
models will benefit from innovative strategies to collect human biological material and clinical information 
from large patient cohorts. Biobanks are needed for the large-scale collection, storage, and distribution of 
human cells and tissues, including normal and patient-derived somatic cells for reprogramming to iPSCs. 
This will increase the statistical power needed to distinguish information from noise.
The availability of good-quality normal and diseased human tissues, derived postmortem or from biopsies, is 
essential. Human tissue research can help define key pathological features of human disease against which 
to validate new in vitro models, but there are challenges to obtaining good-quality human tissue, especially 
from the nervous system. For example, available postmortem brain tissue is often not ideally representative 
of different stages of disease and, in some countries, patient tissue can only be used to study tightly 
specified research questions. Several measures can help improve the situation. Local agreements between 
hospitals and universities or other research institutions would facilitate tissue provision and exchange, and 
the support of patient advocacy organisations is valuable. In the UK, it is easier to get consent to use human 
tissue in a more open-ended way, and that experience could be shared with other countries.
Clinical in vivo studies with volunteers provide gold-standard data relevant to validating innovative in vitro
models, especially if valid clinical biomarkers can be found that are applicable to in vitro studies. 
Computational models have value in integrating multiscale data and linking clinical biomarkers to underlying 
disease pathways, but more work is needed. A systems approach to researching disease allows the 
mapping of multiple ‘omics data onto tissue samples from patients and their clinical and physiological data. 
New bioinformatics and mathematical tools help generate novel clinical disease classifications and enable 
disease-associated pathways to be investigated.
Provision, sharing and organisation of data
A significant contribution to disease research roadmaps would be support for measures such as tools and 
databases to integrate and share information; encouraging open access publication and data sharing; and 
the appropriate use of patient data and data from clinical trials. For maximum utility and applicability, it is also 
essential that data are shared so that all information can be used to improve biological modelling. This can 
be accomplished by means of a global centralised data or knowledge base. An alternative approach could 
be the construction of different databases that are seamlessly integrated, for example by use of common 
templates, ontologies, and integratable platforms.









The handling and curating of big data needs improving. For example, the value of functional genomics would 
be enhanced if better knowledge management platforms existed and more readily accessible bioinformatics 
platforms were available for biologists and clinicians to manage and interpret large-scale data sets. 
Scientists should be encouraged to enter their data into shared, open-source knowledge bases (e.g., the 
OECD AOP Knowledge Base) to enable vertical and horizontal integration of data within disease areas and 
across diseases. In the USA, all federally funded research must soon be published in an open format and 
the underlying data must also be publicly accessible; the EU has given similar stipulations concerning 
research funded through Horizon 2020.
Kola and Bell published a ‘call to reform the taxonomy of human disease’ and proposed a new, mechanism-
based classification [64]. We identified as a major issue the conceptual and data gaps between in vitro
findings and clinical knowledge. These gaps need to be bridged to maximise available data and to realise a 
mechanism- or, better still, pathways-based classification of human diseases. An AOP disease pathway
concept provides a means to connect these currently divided fields and provide missing data (Figure 3).
Data mining by computer can capture knowledge at all levels of biological complexity, which can help 
populate disease AOPs. Regulatory agencies should consider offering academic researchers access to their 
databases and, thus, foster data-mining opportunities. Disease maps and models should be created that 
build on disease-specific as well as generic information, to enable in silico experimentation and the 
prediction of knowledge gaps. Appropriate anonymisation standards need to be developed. In the EU, there 
are member state differences over data protection that will take some time to resolve, but it has significant 
implications for health research. These are important first steps, but more is needed. Funding bodies and 
policy development could support knowledge bases or platforms where disease pathway-relevant research 
would be held under a common set of standards, so that data can be submitted in a way that facilitates their 
use by others.
Policy and funding frameworks
To build on the advances made with human-specific models and to give a clear direction for more effectively 
incorporating their use into biomedical research over the next decade, strategic policy and funding 
frameworks are essential. Overarching strategic frameworks would prioritise the funding and deployment of 
human-specific models, technologies, and infrastructures over the next 5–10 years. Such strategic 
frameworks would ideally be developed for, and coordinated among, the EU, USA, and other key innovation 
economies, through a transparent process inclusive of all stakeholders, including academic and 
pharmaceutical researchers, research-funding bodies, regional and national regulators and advocacy 
organisations, including health advocacy groups.









Within Europe, the European Commission is well placed to establish high-level strategic bodies to review 
progress in specific disease areas, identify knowledge gaps and propose adaptations to existing strategies, 
by providing research funding and coordination activities. Joint Programming Initiatives 
(http://ec.europa.eu/research/era/joint-programming-initiatives_en.html) already respond to the challenge of 
coordinating research undertaken at member-state level. They could form the basis of a more centralised 
approach also involving EU-funded research projects, with the objective being to establish a shared 
understanding of research needs and opportunities. In the USA, the Tox21 consortium (http://tox21.org/) is 
an example of a crossdisciplinary approach. Tox21 was established by the EPA, the National Institutes of 
Health Chemical Genomics Center, the National Toxicology Program, and more recently, the US Food and 
Drug Administration, in recognition of the failure of animal testing to meet 21st-century regulatory needs. Its 
strategy includes researching, developing, and validating innovative chemical testing methods that 
characterise toxicity pathways using new tools. A similar interagency consortium for biomedical research, led 
by the US National Institutes of Health, would be a valuable development.
It is essential to acknowledge that addressing major societal challenges, such as the current failure rate in 
drug development, requires new policy approaches in addition to innovative science. Workshop participants 
recognised concerns expressed by researchers developing novel techniques about the difficulty in obtaining 
funding for method and model developments that focus solely on human biology, and agreed that 
conservatism within funding agencies favouring traditional animal models represents a barrier to progress. 
To stimulate change, the creation and use of human-specific models could be incentivised; the use of animal 
models and their data should always be scientifically justified. Similarly, it is hoped that any such 
conservatism among journal editors and reviewers can be overcome as increasing numbers of researchers 
recognise the relevance of new and emerging non-animal models and technologies.
Concluding remarks
If the goal of biomedical research is to advance human medicine, we must move decisively away from the 
quest to improve animal models, which are often insufficiently relevant or reliable, and towards the prioritised 
use of human-biology based methods. A new approach is needed to strategically implement advanced 
models and tools to understand human disease pathways at multiple biological scales. Funding and policy 
decisions should drive the development and implementation of 21st-century human-specific scientific 
approaches, to help ensure that recommendations for disease research roadmaps (Box 1) will benefit every 
step of the research and drug development process. A better framework for biomedical research, based on 
mapping human disease pathways at multiple biological scales, would enable new treatments to progress 
‘from bench to bedside’ more quickly and cost-effectively.
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Figure 1. [DE2]Hypothetical ‘disease adverse outcome pathway’ (AOP). An AOP spans many levels of 
biological complexity, starting at the molecular level with a molecular initiating event. This is linked causally 
via key events at cell, tissue, organ, and system levels, resulting in an adverse outcome in the individual. 
Abbreviation: MIE, AOP molecular initiating event.
Figure 2[DE3]. Novel tools and readouts applicable to human-oriented Alzheimer’s disease (AD) research at 
multiple levels of biological complexity. These tools provide information that can be used to map disease 
pathways. Reproduced, with permission, from [65]. Abbreviations: CSF, cerebrospinal fluid; GEP, gene 
expression profiling; GWAS, genome-wide association studies; HVLT, Hopkins verbal learning test; IF HCS, 
immunofluorescence-high content screening; iNCs, induced neuronal cells; iPSCs, induced pluripotent stem 
cells; MEA, microelectrode array; MMSE, mini-mental state examination; MRI, magnetic resonance imaging; 
MRS, magnetic resonance spectroscopy; MS, mass spectrometry; NSCs, neural stem cells; PET, positron 
emission tomography
Figure 3. [DE4]In many disease areas, there is a fundamental disconnect between the concepts, terminology,
and data associated with molecular and/or cellular studies and those associated with clinical approaches. 
The adverse outcome pathway (AOP) framework, applied to biomedical research, would provide the missing 
links by clarifying key events in disease pathways at all relevant biological scales: molecular, cellular, tissue, 









organ, system, and individual. Abbreviation: KE 1, 2, 3, possible key events in an AOP; MIE, AOP molecular 
initiating event that starts the pathway perturbation.
Box 1. Summary of recommendations
A 21st-century roadmap for biomedical research and/or a roadmap for each disease area needs to be 
designed, to provide a strategic approach for utilising human-specific models and innovative technologies. 
One or two research roadmaps could be developed as prototypes, using existing knowledge and making 
full use of human-specific models.
We propose a repurposing of the AOP concept in toxicology to form the basis of understanding human 
disease pathophysiology and improve drug discovery and development in biomedical research.
Effective strategies are required to collect human biological material and clinical information from large 
patient cohorts and healthy individuals, to increase understanding of human diseases and assist the 
validation of new human-specific models in vitro and in silico.
Progress with microfluidic systems will require investment to produce off-the-shelf devices and 
components, perhaps on a modular basis with plug-in connections, to make these systems more use
friendly.
The sharing of ideas, expertise, and concepts between various research communities and clinicians 
needs ongoing facilitation. 21st-century tools often draw on multiple disciplines and there is frequently a 
disconnect between research and clinical data, which could be bridged by means of disease pathways. 
Patient groups should also be involved, because they can facilitate science-driven solutions.
Systems biology approaches, including new bioinformatics and mathematical tools, need further support. 
They will help integrate multiscale data, generate better clinical disease classifications, enable disease-
associated pathways to be investigated, and suggest new research directions.
New databases are needed to integrate and share information. Open-access publication and data
sharing should be not only encouraged, but also required for all publicly funded research. These 
developments require dedicated funding and policy support. Funding agreements could specify that relevant 
research findings are to be input into a common global knowledge base, such as the AOP Knowledge Base,
and other shared, open-source platforms.
Effective data mining will be improved by harmonised standards of patient anonymisation and data 
protection, because this has significant implications for health research.









Overarching strategic frameworks are essential to direct policy initiatives and funding programs to 
essential areas that need further development and to coordinate related activities. These frameworks would 
ideally be coordinated among the EU, USA, and other key innovation economies, through a process of 
dialogue among all stakeholders.
To advance 21st-century human-specific scientific progress, funding should be focussed strategically on 
acquiring critical human information and on developing and validating the necessary new tools, rather than 
on further developing animal models.
Publishing and funding biases in favour of animal studies need to be addressed.
Research-funding bodies are encouraged to prioritise crosscutting efforts to elucidate human disease 
AOPs using a common framework (e.g., the OECD AOP User Handbook).
In the EU and USA, the European Commission and NIH, respectively, are well placed to establish high-
level strategic bodies to review progress in specific disease areas, identify knowledge gaps, and propose 
adaptations to existing strategies, by providing research funding and coordination activities.
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